Compounding Pharmacists Must Use Disclaimer Under Settlement With Chiron
This article was originally published in The Pink Sheet Daily
Executive Summary
Tobi manufacturer Chiron sued the Respiratory Disease Network over promotion and compounding of tobramycin. Under the settlement, marketing materials for the pharmacy network's product must note that it has not been evaluated by FDA.
You may also be interested in...
FDA Compounding Policy To Have Day In Court In December
Ten pharmacies challenging the agency's compounding policy say the lawsuit is an effort to stop "FDA's end-run on the Western States decision," which threw out restrictions on advertising for compounding products.
Dusa Patent Suit Challenges Compounding Of Levulan
New England Compounding Center’s compounding of aminolevulinic acid HCl goes beyond the activities permitted under the FD&C Act, Dusa maintains. The company has also told FDA about its concerns.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.